Physician profile
William C Hicks
NPI 1235161092
$7,013.48
in general payments reported to CMS, 2019-2025
38 companies · $952 in 2025
The $952 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,005 · 2020: $1,771 · 2021: $1,561 · 2022: $771 · 2023: $735 · 2024: $217 · 2025: $952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,904.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,904.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $807.71 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Novartis Pharmaceuticals Corporation | $804.60 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $640.74 | 2021-2025 | |
| Abbvie INC. | $632.77 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $545.05 | 2019-2022 | |
| Lilly USA, LLC | $439.69 | 2019-2025 | Mounjaro, Kisunla, Zepbound |
| Astrazeneca Pharmaceuticals LP | $414.92 | 2020-2025 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $373.87 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $358.99 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $290.75 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $282.84 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Daiichi Sankyo INC. | $174.92 | 2019-2020 | |
| Amgen INC. | $171.54 | 2019-2023 | Repatha, Otezla |
| Sumitomo Pharma America, INC. | $145.33 | 2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $120.71 | 2019-2021 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Hicks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.